Oncothyreon

Diana Hausman, M.D. has been named vice president, Clinical Development at Oncothyreon. Dr. Hausman will be responsible for planning and implementing the clinical development program for the company’s pipeline of oncology product candidates.

“Dr. Hausman is an experienced oncologist who brings an extensive background in drug development to her new role at Oncothyreon,” said Robert L. Kirkman, M.D, the company’s president and chief executive officer. “Her leadership and knowledge of all aspects of cancer drug development will be very important as we prepare to move both PX-866, our inhibitor of PI-3 kinase, and PX-478, our inhibitor of hypoxia inducible factor 1-alpha, into Phase 2 trials. We are delighted to have her join our team.”

Dr. Hausman was previously at Zymogenetics, Inc., where she held a number of clinical research positions from 2005 to 2009, most recently as senior director of Clinical Research with responsibility for all therapeutic areas, including oncology, autoimmune disease and virology. Prior to Zymogenetics, Dr. Hausman led a global drug development team at Berlexfrom 2002 until 2005. Dr. Hausman will assume her new role at Oncothyreon on September 1, 2009.

Sign up today for Contracting &Outsourcing 2009!